language_icon
EN
HI

Orchid Pharma Share price

ORCHPHARMA

502.3

29.35 (-5.52%)
NSE
BSE
Last updated on 27 Mar, 2026 | 15:40 IST
Today's High

530.65

Today's Low

493.85

52 Week Low

489.00

52 Week High

899.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Orchid Pharma Chart

Orchid Pharma Share Key Metrics

Volume
1.96 L
Market Cap
2547.62 CR
LTQ@LTP
4@502.30
ATP
509.26
Var Margin
21.47 %
Circuit Range
425.35-637.95
Delivery %
44.72 %
Value
9.99 CR
ASM/GSM
No
Market Lot
1

Summary

At 27 Mar, 2026 | 15:40, Orchid Pharma share price stands at ₹502.3, showing a 29.35% -5.52 for the day. The stock’s intraday movement has stayed between ₹493.85 and ₹530.65, while on a 52-week basis it has fluctuated from ₹489.00 to ₹899.00.
In terms of trading activity, Orchid Pharma has recorded a volume of 196180 shares, with a market capitalisation of ₹50719105. The stock’s Average Traded Price (ATP) stands at ₹50926, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 4,50230. The stock operates within a circuit range of ₹425.35-637.95, with a Value of ₹9.99 CR. The Delivery Percentage for the day is 44.72%. Additionally, Orchid Pharma currently falls under the No framework, and trades with a market lot size of 1.

Orchid Pharma Fundamentals

View More
P/E Ratio

135.34

P/B Ratio

2.02

Div. Yield

0

Sector P/E

58.52

Sector P/B

3.1

Sec. Div. Yield

0.6

Orchid Pharma Resistance and Support

Pivot 531.7

Resistance

First Resistance

550.9

Second Resistance

570.15

Third Resistance

589.35

Support

First Support

512.45

Second Support

493.25

Third Support

474

Orchid Pharma Futures & Options

Data Not Found

Orchid Pharma Shareholding Pattern

View More
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

69.84%

Mutual Fund

17.46%

Insurance

0.85%

Foreign Institutional Investors

2.53%

Domestic Institutional Investors

0.68%

Retail

8.64%

Others

0%

Total Promoters
MAR '24
69.84%
JUN '24
69.84%
SEP '24
69.84%
DEC '24
69.84%

Orchid Pharma Corporate Actions

DateAgenda
2026-02-11Quarterly Results
2025-11-11Quarterly Results
2025-08-12Quarterly Results
2025-05-26Audited Results
2025-02-12Quarterly Results

Orchid Pharma News

Orchid Pharma Limited

Orchid Pharma announced that the NCLT has reserved its order regarding the amalgamation scheme with Dhanuka Laboratories Limited. The formal pronouncement is scheduled for March 18, 2026, marking a significant step in the merger process.
Mar 18 2026 21:03:00

Orchid Pharma Ltd - 524372 - Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited (''Amalgamating Company'') With Orchid Pharma Limited (''Amalgamated Company'') And Their Respective Shareholders And Creditors (''The Scheme'') Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Orchid Pharma's amalgamation scheme with Dhanuka Laboratories had its NCLT order reserved for formal pronouncement today, March 18, 2026. The company will notify exchanges upon receipt of the official order copy.
Mar 18 2026 21:03:00
Read More

About Orchid Pharma

NSE : 926  
BSE : 524372  
ISIN : INE191A01027  

Orchid Chemicals & Pharmaceuticals Limited (ORCHID) as incorporated as a Public Limited Company on July 01 1992 under the Companies Act 1956. The Company obtained Certificate of Commencement of Business on October 15 1992. ORCHID has its registered office at Madras ORCHID hasset up a 100% Export Oriented Unit for the manufacture of 7 ADCA (intermediate) Cephalexin Cefradine and Cefadroxyl bulk drugs at a cost of Rs.1195 lakhs in technical and financial collaboration with Sintofarm SPA Italy. This unit is located at SIDCO Pharmaceutical Zone Alathur Tamilnadu. The Project was completed two months ahead ofschedule and after successful trial runs in Jan-94 commercial operations commenced from Feb. 94. In Feb 94 ORCHID undertook a Scheme at a cost of Rs.160 lakhs for better recovery of solvents backward integration and process optimization. During its first two months of operations the Company''s unit achieved a capacity utilization of 80% and produced 12.1 tonnes of Cephalexin out of which 11.7 tonnes (97%) was exported.The products are exported to Germany Italy Switzerland Holland Spain Cyprus Hongkong Singapore etc. and have been well received in the International Markets resulting in repeat orders.

Read More

Orchid Pharma Management

NamePosition
Mr. Ram Gopal Agarwal Chairman & Non-Exe.Director
Mr. Manish Dhanuka Managing Director
View More

Orchid Pharma FAQs

The Buying Price of Orchid Pharma share is 502.3 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Orchid Pharma stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Orchid Pharma, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Orchid Pharma shares is 135.34. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Orchid Pharma shares is 2.02. Useful to assess the stock's value relative to its book value.

To assess Orchid Pharma’s valuation compare Sector P/E, P/B which are 58.52 & 3.1 with sector averages, along with growth rates and financial metrics.

The Market Cap of Orchid Pharma is 2547.62 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Orchid Pharma share price is 899.00 & 489.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Orchid Pharma belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost